An Open-label, Randomized, Single-dose, Two-way Crossover Bioequivalence Study Assessing Subjects Receiving Tipranavir 500 mg Stored at Controlled Temperature (Testproduct 30°C/70% RH) Compared With Tipranavir 500 mg Stored at Controlled Refrigerated Conditions (Reference Product 2-8°C), Orally Co-administered With Ritonavir 200 mg Under Fasting Conditions to Healthy Male and Female Volunteers
Latest Information Update: 06 Nov 2021
At a glance
- Drugs Tipranavir (Primary) ; Ritonavir
- Indications HIV-1 infections
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 09 Oct 2014 New trial record